ARCHIMED, a private equity firm specializing in healthcare, has successfully sold DIESSE to Fremman Capital, marking a significant milestone in its five-year partnership with the clinical diagnostics company. This transaction has yielded a remarkable return of 4.6 times the invested capital for shareholders.

DIESSE has undergone a transformation during its time under ARCHIMED's ownership, evolving into a prominent innovator in the clinical diagnostics sector. The sale reflects ARCHIMED's commitment to enhancing the value of its portfolio companies and delivering substantial returns to its investors.

This deal is part of a series of strategic moves by ARCHIMED, which has also recently finalized the acquisition of IBA Lifesciences GmbH by Cube Biotech. Additionally, the firm achieved a fivefold return on its investment by selling a majority stake in Ad-Tech to Nihon Kohden, a Tokyo-listed company.

ARCHIMED continues to expand its portfolio with acquisitions such as SeqCenter, a company specializing in advanced DNA and RNA gene sequencing, and FIM Medical, which focuses on medical devices for vision, audio, and respiratory care. The firm has also acquired Jeisys Medical, known for its aesthetic medicine devices.

Overall, ARCHIMED's recent activities underscore its strategic approach to investing in and enhancing healthcare companies, ultimately benefiting its investors and the broader medical community.